NASDAQ:WVE
Wave Life Sciences, Inc.
Wave Life Sciences, Inc.'s revenue fell 60.5% in fiscal 2025 to $42.7M while operating margin fell to −504.1%. Free cash flow was −$188.2M, −440.5% of revenue, and the diluted share count rose 22.0%.Summary generated from Wave Life Sciences, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$42.7M
Revenue growth−60.5%
Revenue, 5-yr CAGR+16.3%
Gross marginn/a
Operating margin−504.1%
Net margin−478.3%
ROICn/a
Return on equity−56.2%
Debt / equityn/a
Free cash flow−$188.2M
FCF margin−440.5%
Share count change+22.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 41 | 4 | 113 | 108 | 43 |
| Operating income | −127 | −163 | −68 | −110 | −215 |
| Net income | −122 | −162 | −58 | −97 | −204 |
| Free cash flow | −90 | −129 | −21 | −152 | −188 |
Recent filings
- 4Insider transaction report
Oct 7, 2026 - 4Insider transaction report
Oct 7, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KResults of a shareholder vote
Jun 26, 2026 - 8-KRegulation FD disclosure
May 18, 2026 - DEF 14AProxy statement
May 7, 2026 - 10-K/AAmended annual report for the fiscal year ended Dec 31, 2025
Apr 30, 2026